{"gene":"ACKR1","run_date":"2026-06-09T22:02:38","timeline":{"discoveries":[{"year":1995,"finding":"DARC (ACKR1) expressed on erythrocytes internalizes radiolabeled chemokine ligands upon transfection, whereas endothelial DARC expression is maintained in Duffy-negative individuals who lack erythrocyte DARC, indicating tissue-specific regulatory mechanisms for DARC expression.","method":"Radiolabeled ligand internalization assay, immunohistochemistry, biochemical and molecular biological analysis of tissues from Duffy-negative individuals","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (radiolabeled internalization, IHC, biochemistry, molecular biology), replicated across tissues, foundational study","pmids":["7699323"],"is_preprint":false},{"year":2000,"finding":"DARC knockout mice lacking both erythroid and endothelial DARC show exaggerated inflammatory infiltrates in lung and liver following LPS challenge, and erythrocytes from null mice lack CXC and CC chemokine-binding activity, demonstrating DARC functions as a chemokine sink that modulates inflammation intensity.","method":"Targeted gene disruption (knockout mice), LPS challenge model, hematological analysis, chemokine binding assay on erythrocytes","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotype, multiple readouts, replicated concept across multiple labs","pmids":["10961863"],"is_preprint":false},{"year":2000,"finding":"Deletion of murine Dfy (DARC ortholog) reduces neutrophil migration into the peritoneal cavity and intestines/lungs following LPS/thioglycolate challenge, establishing a role for DARC in the neutrophil migratory process, though the receptor appears functionally redundant for most developmental and immune parameters.","method":"Targeted gene deletion (Dfy−/− mice), peritoneal inflammation models (LPS and thioglycolate), histological analysis of neutrophil recruitment","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotype, multiple inflammation models, replicated in same paper","pmids":["10757794"],"is_preprint":false},{"year":2003,"finding":"DARC expressed on high endothelial venules (HEV) selectively binds pro-inflammatory chemokines (CXCL1, CXCL5, CCL2, CCL5, CCL7) but not lymphoid chemokines (CCL21, CCL19, CXCL12, CXCL13); DARC-bound CCL2 failed to induce Ca2+ elevation in CCR2B-expressing cells, indicating DARC down-regulates pro-inflammatory chemokine activity upon binding without G-protein signaling.","method":"Competitive binding experiments with 20 chemokines, cytosolic Ca2+ elevation assay, targeted gene disruption, lymphocyte trafficking assay","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro binding assays with functional readout (Ca2+ signaling), KO mice, multiple chemokines tested","pmids":["13679391"],"is_preprint":false},{"year":2005,"finding":"DARC tyrosines 30 and 41 are sulphated; sulphated tyrosine 41 is essential for binding of P. vivax Duffy binding protein (PvDBP) and P. knowlesi (PkDaBP), and participates in association with chemokines MCP-1, RANTES, and MGSA but not IL-8; sulphated tyrosine 30 is required for IL-8 binding; a soluble sulphated N-terminal DARC domain blocks PvDBP/PkDaBP binding to RBCs with IC50 ~5 nM.","method":"Tyrosine-to-phenylalanine mutagenesis, cell-based binding assays, soluble peptide inhibition assay","journal":"Molecular microbiology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of specific residues with functional binding readouts, multiple chemokine ligands tested, inhibition experiments","pmids":["15720550"],"is_preprint":false},{"year":2006,"finding":"DARC on vascular endothelium interacts directly with KAI1 (CD82) on tumor cells; this interaction leads to inhibition of tumor cell proliferation, induction of senescence, and modulation of TBX2 and p21 expression; DARC knockout mice showed significantly compromised KAI1-mediated metastasis suppression.","method":"Yeast two-hybrid screen, DARC knockout mouse metastasis model, cell proliferation assays, gene expression analysis","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — yeast two-hybrid identification plus in vivo KO validation, multiple cellular readouts, mechanistic pathway placement","pmids":["16862154"],"is_preprint":false},{"year":2006,"finding":"DARC on erythrocytes clears angiogenic CXC chemokines (produced by prostate cancer cells) in vitro, reducing endothelial cell chemotaxis; in DARC-deficient mice bearing prostate tumors, intra-tumor angiogenic chemokine concentrations are elevated, tumor vessel density is increased, and tumor growth is greatly augmented.","method":"In vitro chemokine clearance assay with wild-type vs. DARC-deficient erythrocytes, transgenic prostate cancer model in DARC KO mice, ELISA, vessel density quantification","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro functional assay plus in vivo KO model with multiple orthogonal readouts","pmids":["16394268"],"is_preprint":false},{"year":2007,"finding":"DARC on endothelial cells attenuates angiogenesis by inducing cellular senescence; in DARC-expressing HCEC cells, capillary formation was initially enhanced then attenuated with cells undergoing senescence, while blocking DARC's N-terminal chemokine-binding domain with anti-Fy6 antibody or adding excess IL-8 increased capillary formation; DARC knockout mice showed more capillary formation in Matrigel plugs.","method":"In vitro Matrigel angiogenesis assay, in vivo Matrigel plug assay in DARC KO mice, anti-DARC antibody blocking, IL-8 competition","journal":"Angiogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mice plus in vitro assays with blocking antibody, single lab","pmids":["17955335"],"is_preprint":false},{"year":2007,"finding":"DARC (Darc) regulates bone mineral density (BMD) negatively by promoting osteoclast formation; anti-DARC antibody blocked multinucleated osteoclast formation in vitro; DARC from a high-BMD strain binds chemokines (known to regulate osteoclast formation) with reduced affinity compared to low-BMD strain DARC.","method":"QTL mapping, Darc knockout skeletal phenotyping, in vitro osteoclast formation assay with antibody blockade, chemokine binding affinity comparison","journal":"Genome research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO phenotype plus in vitro antibody blocking assay plus binding affinity comparison, single lab","pmids":["17416748"],"is_preprint":false},{"year":2009,"finding":"DARC on red blood cells (RBCs) sequesters CXCL1 from plasma; in DARC-deficient mice, LPS-induced PMN migration into alveolar space was elevated >2-fold with increased alveolar CXCL1 and CXCL2/3, while PMN adhesion to endothelium and interstitial space was reduced; DARC on non-hematopoietic cells had only minor effects in this model.","method":"Darc−/− mice, LPS-induced acute lung injury model, bone marrow chimeras distinguishing hematopoietic vs. endothelial DARC, ELISA, flow cytometry","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — bone marrow chimera experiments separating hematopoietic vs. non-hematopoietic DARC, KO mice, multiple chemokine readouts","pmids":["19499525"],"is_preprint":false},{"year":2009,"finding":"DARC rs12075 (Asp42Gly) non-synonymous polymorphism is a major regulator of erythrocyte DARC-mediated cytokine binding, accounting for ~20% of variability in serum MCP-1 and also regulating IL-8 and RANTES concentrations; clotting and exogenous heparan sulfate release chemokines from DARC, identifying two mechanisms for reservoir chemokine release.","method":"Genome-wide association study (n=9598), family-based genetic linkage, quantitative immunoflow cytometry, ex vivo chemokine release assays with heparan sulfate/clotting","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — large GWAS plus ex vivo functional release assays, but functional mechanism inferred from genetics and ex vivo rather than direct molecular reconstitution","pmids":["20040767"],"is_preprint":false},{"year":2011,"finding":"P. vivax Duffy-binding protein RII (RII-PvDBP) dimerization is required for and driven by DARC receptor engagement; crystallographic, solution, and functional studies show that receptor binding induces dimerization; dimerization is required for red blood cell binding and accounts for action of naturally acquired blocking antibodies.","method":"X-ray crystallography, solution studies, functional RBC binding assays, antibody blocking experiments","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with solution and functional studies, multiple orthogonal methods in a single rigorous study","pmids":["21743458"],"is_preprint":false},{"year":2014,"finding":"The DARC N-terminal ectodomain forms an amphipathic helix upon PvDBP-RII binding; crystal structures reveal two DBP-RII molecules sandwiching one or two DARC ectodomains creating heterotrimer/heterotetramer architectures; point mutations of DARC contact residues result in complete loss of RBC binding by DBP-RII; isothermal titration calorimetry shows multi-step binding pathway.","method":"NMR epitope mapping, X-ray crystallography (two crystal structures), isothermal titration calorimetry, site-directed mutagenesis, RBC binding assays","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR plus X-ray crystallography plus ITC plus mutagenesis plus functional binding assays in a single rigorous study","pmids":["24415938"],"is_preprint":false},{"year":2014,"finding":"Endothelial DARC mediates abluminal-to-luminal transcytosis of inflammatory chemokines across the blood-brain barrier; erythrocyte DARC functions as a chemokine reservoir determining plasma chemokine levels; endothelial DARC (not erythrocyte DARC) is required for full EAE pathogenesis as shown by bone marrow chimera experiments.","method":"In vitro BBB model, Darc−/− mice in EAE model, bone marrow chimeras separating erythrocyte vs. endothelial DARC, chemokine transcytosis assay","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — bone marrow chimera experiments separating cell-type specific functions, in vitro transcytosis assay, in vivo EAE model with multiple readouts","pmids":["24625696"],"is_preprint":false},{"year":2015,"finding":"S. aureus hemolytic leukocidins LukED and HlgAB use DARC as their receptor on erythrocytes to mediate lysis; HlgA and LukE bind directly to DARC through different regions; DARC expression level directly correlates with susceptibility to toxin-mediated lysis; DARC overexpression is sufficient to render non-erythroid cells susceptible; LukED and HlgAB support S. aureus hemoglobin acquisition in a DARC-dependent manner.","method":"Human erythrocyte DARC polymorphism analysis, DARC overexpression in non-erythroid cells, direct binding assays, hemolysis assays, bacterial growth assays","journal":"Cell host & microbe","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding assays, overexpression sufficiency, natural human variants used, multiple functional readouts","pmids":["26320997"],"is_preprint":false},{"year":2016,"finding":"DARC on bone marrow macrophages (DARC+ BM macrophages) binds CD82/KAI1 on LT-HSCs and stabilizes CD82 surface expression, promoting TGF-β1/Smad3-mediated CDK inhibitor induction and cell-cycle inhibition; ablation of DARC+ BM macrophages decreased surface CD82 on LT-HSCs, causing cell-cycle entry and differentiation.","method":"Cd82−/− mice, macrophage ablation experiments, flow cytometry, TGF-β1/Smad3 signaling analysis, cell cycle assays","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mice, macrophage ablation loss-of-function, signaling pathway identification, multiple cell biological readouts","pmids":["26996598"],"is_preprint":false},{"year":2017,"finding":"DARC (ACKR1) is exquisitely restricted to post-capillary and small collecting venules (not arteries, arterioles, capillaries, veins, or lymphatics) in all murine tissues; DARC is concentrated at endothelial cell-cell junctions; adhesive leukocyte-endothelial interactions are restricted to DARC+ venules as shown by intravital microscopy.","method":"Anti-mouse DARC monoclonal antibody generation, immunostaining of murine tissues, intravital microscopy, single-cell suspension analysis","journal":"BMC biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — purpose-built monoclonal antibody, multiple tissue types, intravital microscopy confirming functional correlation with leukocyte adhesion","pmids":["28526034"],"is_preprint":false},{"year":2017,"finding":"DARC extracellular domain conformation changes during reticulocyte maturation; although total DARC protein is constant throughout maturation, selective exposure of the DBP-binding site within DARC on CD71high/RNAhigh immature reticulocytes (not mature erythrocytes) explains P. vivax tropism for immature reticulocytes.","method":"CD71/RNA flow cytometry of reticulocyte populations, recombinant DBP binding assays, anti-DARC monoclonal antibody binding assays across reticulocyte maturation stages","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional binding assays across differentiation stages, single lab, mechanism inferred from conformational change without direct structural data","pmids":["28754683"],"is_preprint":false},{"year":2018,"finding":"ACKR1 is enriched within endothelial junctions of venular walls and presents CXCL2 (produced by transmigrating neutrophils) as a junctional chemokine depot; ACKR1-presented CXCL2 enables efficient unidirectional luminal-to-abluminal neutrophil migration through EC junctions; this pro-migratory activity of CXCL2 depends on ACKR1.","method":"Confocal intravital microscopy of cytokine-stimulated mouse cremaster muscles, ACKR1 knockout mice, neutrophil emigration analysis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo intravital microscopy with KO mice, defined chemokine and receptor, specific directional migration phenotype","pmids":["30446388"],"is_preprint":false},{"year":2019,"finding":"DARC on endothelial cells is the critical target for S. aureus LukED and HlgAB leukocidin-mediated lethality in mice; these toxins injure primary human endothelial cells in a DARC-dependent manner; mice with DARC-deficient endothelial cells are resistant to toxin-mediated lethality and show reduced tissue damage during bloodstream infection.","method":"DARC-deficient endothelial cell mice (conditional KO), toxin challenge experiments, primary human endothelial cell injury assays, S. aureus bloodstream infection model","journal":"Cell host & microbe","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional endothelial cell-specific KO mice, human cell validation, both toxin challenge and infection models","pmids":["30799265"],"is_preprint":false},{"year":2019,"finding":"DARC on erythrocyte progenitors binds SDF-1 (CXCL12) in a DARC-dependent and conformation-dependent manner; SDF-1 binding is absent on mature erythrocytes due to conformational changes during erythroid development; SDF-1 binding to mature erythrocytes can be induced by pre-treating with IL-8 or specific anti-DARC antibodies that alter DARC conformation.","method":"Flow cytometry binding assays with recombinant SDF-1, anti-DARC antibody competition, IL-8 pre-treatment experiments on erythrocytes at different maturation stages","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding assays with induction/competition experiments, single lab, functional implications inferred","pmids":["31700087"],"is_preprint":false},{"year":2021,"finding":"ACKR1 upregulation in brain microvascular endothelial cells favors transcellular over paracellular T-cell diapedesis across the blood-brain barrier; loss of endothelial ACKR1 reduced transcellular T-cell diapedesis under physiological flow in vitro; ACKR1 is upregulated in venular endothelial cells during EAE.","method":"RNA-seq transcriptome profiling of pMBMECs, ACKR1 protein upregulation confirmation, ACKR1 KO in pMBMECs under flow conditions, T-cell diapedesis assay","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO loss-of-function in vitro under physiological flow, RNA-seq plus protein validation, single lab","pmids":["34524684"],"is_preprint":false},{"year":2023,"finding":"Endothelial ACKR1 expression is induced by contact with neutrophils (not other blood cells) and is regulated by NF-κB; upon removal of blood, ACKR1 protein is rapidly secreted via extracellular vesicles; endogenous ACKR1 does not signal (no response to IL-8 or CXCL1 stimulation confirmed).","method":"Primary human lung microvascular endothelial cell culture with whole blood/isolated cell fractions, NF-κB inhibition, extracellular vesicle characterization, IL-8/CXCL1 stimulation signaling assay","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro methods, NF-κB regulation and EV secretion identified, negative signaling result confirmed, single lab","pmids":["37153544"],"is_preprint":false},{"year":2023,"finding":"Crystal structure of PvDBP-RII bound to sulphated DARC peptide shows that sulphate on DARC tyrosine 41 binds to a charged pocket on PvDBP-RII; molecular dynamics simulations, affinity measurements, and parasite growth-inhibition experiments confirm importance of this sulphated interaction; the epitope for vaccine-elicited growth-inhibitory antibody DB1 is revealed.","method":"X-ray crystallography, molecular dynamics simulations, affinity measurements, parasite growth-inhibition experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus molecular dynamics plus affinity measurements plus functional parasite growth inhibition in a single rigorous study","pmids":["37336887"],"is_preprint":false},{"year":2024,"finding":"ACKR1 in endothelial cells regulates FOLR2+ macrophage migration to injured peritendinous sites; Ackr1−/− bone marrow chimeras showed a decline of FOLR2+ macrophages at the injury site, demonstrating ACKR1-regulated macrophage recruitment is involved in tendon adhesion/regeneration.","method":"Single-cell RNA sequencing, bone marrow transplantation chimeras (Lysm-Cre;R26RtdTomato→Ackr1−/− mice), proteomics, in vitro experiments with human cells","journal":"Bone research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bone marrow chimera loss-of-function with defined macrophage subset readout, supported by scRNA-seq and proteomics, single lab","pmids":["38714649"],"is_preprint":false},{"year":2024,"finding":"Endothelial cells with high ACKR1 expression (ACKR1hi ECs) promote aortic dissection (TAAD) through the ACKR1/NF-κB/SPP1 signaling pathway; ACKR1 knockdown suppressed NF-κB signaling and SPP1 expression, reducing macrophage migration and proinflammatory polarization; ACKR1 overexpression exacerbated TAAD; the drug amikacin targets this pathway.","method":"Single-cell transcriptomics, gain- and loss-of-function ACKR1 modulation in ECs, NF-κB pathway analysis, macrophage migration/polarization assays, in vivo TAAD mouse model, molecular docking","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain and loss-of-function experiments with defined signaling pathway, in vivo mouse model, single lab","pmids":["39692014"],"is_preprint":false},{"year":2010,"finding":"DARC on Duffy-positive sickle reticulocytes (SRe) maintains α4β1 integrin in a higher chemokine-sensitive affinity state; IL-8 increased Duffy-positive SRe adhesion to VCAM-1 and fibronectin but not Duffy-negative SRe; IL-8 induced α4β1 clustering (not affinity change) in Duffy-positive SRe, demonstrating DARC-dependent modulation of integrin activation state.","method":"Static adhesion assays, flow cytometry with conformation-sensitive anti-β1 antibody, immunofluorescence microscopy","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — comparison of Duffy-positive vs. negative SRe with conformation-sensitive antibody and multiple functional readouts, single lab","pmids":["21088296"],"is_preprint":false},{"year":2017,"finding":"DARC expressed in pancreatic cancer cells inhibits CXCR2 signaling and downstream STAT3 activation; DARC knockdown significantly increased cell proliferation in high-DARC cells by activating STAT3; CXCR2-induced STAT3 activation promotes cell cycle progression, inhibits apoptosis, induces angiogenesis, and enhances invasiveness, all of which DARC suppresses by down-regulating CXCR2 signaling.","method":"DARC knockdown, CXCR2 knockdown, STAT3 activation assay (EMSA), cell proliferation assays, apoptosis assays, clinical specimen analysis","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown experiments with defined signaling pathway readout (STAT3/EMSA), single lab","pmids":["28214673"],"is_preprint":false},{"year":2024,"finding":"Anti-ACKR1 autoantibodies from COVID-19 survivors target the N-terminal extracellular domain of ACKR1 on endothelial cells and mediate antibody-dependent cellular cytotoxicity (ADCC) via PBMCs; blocking peptide or liposome ACKR1 recombinant protein alleviated ADCC; purified IgG did not directly trigger apoptosis or increase barrier permeability.","method":"Purified IgG from patient plasma, ADCC assay, ACKR1 blocking peptide/recombinant protein, human vein endothelial cell assays, flow cytometry","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — purified IgG functional assays with blocking peptide rescue, multiple readouts, single lab","pmids":["38740432"],"is_preprint":false}],"current_model":"ACKR1 (DARC) is an atypical, non-G-protein-coupled seven-transmembrane chemokine receptor expressed on erythrocytes and post-capillary venular endothelial cells that binds both CXC and CC pro-inflammatory chemokines (but not lymphoid chemokines) without conventional signal transduction, functioning as a chemokine sink/reservoir on erythrocytes to regulate circulating chemokine levels, and as a transcytosis conduit and junctional chemokine presenter on venular endothelium to guide directional neutrophil and T-cell diapedesis; its N-terminal ectodomain—where sulphated tyrosines 30 and 41 are critical—also serves as the obligate receptor for Plasmodium vivax/knowlesi invasion of red blood cells, the target for S. aureus hemolytic leukocidins (LukED/HlgAB), and a binding partner for the metastasis suppressor KAI1/CD82 that triggers tumor cell senescence."},"narrative":{"mechanistic_narrative":"ACKR1 (DARC/Duffy) is an atypical seven-transmembrane chemokine receptor that binds pro-inflammatory CXC and CC chemokines without coupling to G-protein signaling, instead acting as a high-capacity chemokine handling system that shapes inflammation [PMID:10961863, PMID:13679391, PMID:37153544]. On erythrocytes it functions as a chemokine sink/reservoir: it internalizes and sequesters ligands such as CXCL1, CCL2, CCL5, and CXCL8 from plasma, and its loss elevates circulating and tissue chemokine levels and exaggerates inflammatory leukocyte infiltration [PMID:7699323, PMID:10961863, PMID:19499525]. Release of reservoir chemokines is triggered by clotting and heparan sulfate, and the common rs12075 (Asp42Gly) variant is a major determinant of erythrocyte chemokine-binding capacity [PMID:20040767]. On post-capillary venular endothelium, where it concentrates at cell-cell junctions, ACKR1 mediates abluminal-to-luminal transcytosis of chemokines and presents them as junctional depots—notably neutrophil-derived CXCL2—to direct unidirectional transendothelial neutrophil and T-cell migration [PMID:24625696, PMID:28526034, PMID:30446388, PMID:34524684]. Ligand recognition depends on a sulphated N-terminal ectodomain in which tyrosine 30 supports CXCL8 binding and tyrosine 41 supports binding of other chemokines [PMID:15720550]. This same ectodomain is the obligate erythrocyte receptor for Plasmodium vivax/knowlesi invasion: binding of the parasite Duffy-binding protein RII drives its dimerization, and the sulphated tyrosine 41 docks into a charged pocket on PvDBP-RII, with conformational exposure of this site on immature reticulocytes explaining parasite tropism [PMID:15720550, PMID:21743458, PMID:24415938, PMID:37336887, PMID:28754683]. The N-terminal ectodomain is also the receptor for the Staphylococcus aureus leukocidins LukED and HlgAB, mediating erythrocyte lysis, endothelial injury, and toxin lethality in vivo [PMID:26320997, PMID:30799265]. Independently, endothelial and bone-marrow-macrophage ACKR1 binds the metastasis suppressor KAI1/CD82, stabilizing its surface expression to induce tumor-cell senescence and to enforce TGF-β1/Smad3-mediated quiescence of long-term hematopoietic stem cells [PMID:16862154, PMID:26996598].","teleology":[{"year":1995,"claim":"Established that erythrocyte DARC actively internalizes chemokine ligands and that erythroid and endothelial DARC are independently regulated, defining DARC as a chemokine-handling receptor rather than a passive binder.","evidence":"Radiolabeled ligand internalization in transfectants plus IHC and biochemistry in Duffy-negative tissues","pmids":["7699323"],"confidence":"High","gaps":["Did not establish whether internalized chemokine is degraded or recycled","No demonstration of a signaling-independent mechanism"]},{"year":2000,"claim":"Knockout mice showed that DARC functions as a chemokine sink modulating inflammation intensity and neutrophil migration, moving the receptor from in vitro binder to in vivo immunoregulator.","evidence":"Two independent Darc-null mouse lines challenged with LPS/thioglycolate, with erythrocyte chemokine-binding assays","pmids":["10961863","10757794"],"confidence":"High","gaps":["Could not separate erythroid from endothelial contributions","Receptor appeared largely redundant for development and most immune parameters"]},{"year":2003,"claim":"Demonstrated chemokine selectivity (pro-inflammatory but not lymphoid) and that DARC binding silences chemokine activity without triggering Ca2+ flux, defining its non-signaling decoy/scavenger character.","evidence":"Competitive binding of 20 chemokines, Ca2+ flux assay in CCR2B cells, KO mice","pmids":["13679391"],"confidence":"High","gaps":["Did not resolve the fate of bound chemokine on endothelium","Mechanism of presentation versus sequestration unresolved"]},{"year":2005,"claim":"Mapped the structural basis of ligand recognition to sulphated tyrosines, showing Tyr41 and Tyr30 differentially govern chemokine and parasite-protein binding via the N-terminal ectodomain.","evidence":"Tyr-to-Phe mutagenesis, cell-based binding, and soluble peptide inhibition of PvDBP/PkDaBP","pmids":["15720550"],"confidence":"High","gaps":["No atomic structure of the sulphated interface at this stage","Did not address conformational regulation of the ectodomain"]},{"year":2006,"claim":"Linked DARC to tumor biology in two ways: as a direct KAI1/CD82 binding partner inducing tumor-cell senescence, and as an erythrocyte clearer of angiogenic chemokines limiting tumor vascularization.","evidence":"Yeast two-hybrid plus KO metastasis model; erythrocyte chemokine clearance assays and DARC-KO prostate tumor model","pmids":["16862154","16394268"],"confidence":"High","gaps":["Did not define the structural KAI1-binding interface on DARC","Downstream senescence pathway only partially mapped (TBX2, p21)"]},{"year":2007,"claim":"Extended the senescence/anti-angiogenic role to endothelial DARC and identified a negative role in bone density via osteoclast regulation, broadening the physiological reach of chemokine handling.","evidence":"Matrigel angiogenesis assays with anti-Fy6 blockade and KO mice; QTL mapping and in vitro osteoclast assays with chemokine affinity comparisons","pmids":["17955335","17416748"],"confidence":"Medium","gaps":["Single-lab studies","Causal chemokine intermediaries in osteoclast and angiogenesis phenotypes not fully defined"]},{"year":2009,"claim":"Bone-marrow chimeras separated erythrocyte from endothelial DARC, showing erythrocyte DARC sets plasma chemokine levels while endothelial DARC governs leukocyte adhesion and transmigration.","evidence":"Darc-/- mice with bone marrow chimeras in LPS acute lung injury, ELISA and flow cytometry","pmids":["19499525"],"confidence":"High","gaps":["Molecular mechanism of endothelial chemokine presentation not yet defined","Did not address junctional localization"]},{"year":2010,"claim":"Connected reservoir handling to genetics and to cell-adhesion modulation, with rs12075 controlling erythrocyte chemokine binding and DARC tuning integrin activation on reticulocytes.","evidence":"GWAS (n=9598) with ex vivo chemokine-release assays; static adhesion and conformation-sensitive integrin assays on sickle reticulocytes","pmids":["20040767","21088296"],"confidence":"Medium","gaps":["Release mechanism inferred from ex vivo assays, not reconstituted","Integrin modulation shown for clustering rather than affinity change in a single system"]},{"year":2014,"claim":"Defined the structural mechanism of parasite engagement (PvDBP-RII dimerization-coupled binding with the ectodomain forming an amphipathic helix) and established endothelial DARC as the transcytosis conduit required for CNS inflammation.","evidence":"X-ray crystallography, NMR, ITC and RBC binding mutagenesis for PvDBP; BBB transcytosis model and EAE chimeras for endothelial function","pmids":["21743458","24415938","24625696"],"confidence":"High","gaps":["Stoichiometry of physiological invasion complexes on intact erythrocytes not directly observed","Transcytosis machinery cooperating with DARC not identified"]},{"year":2015,"claim":"Identified DARC as the erythrocyte receptor for S. aureus leukocidins LukED and HlgAB, with expression level dictating lysis susceptibility and supporting bacterial hemoglobin acquisition.","evidence":"Natural human polymorphism analysis, DARC overexpression sufficiency, direct binding and hemolysis assays","pmids":["26320997"],"confidence":"High","gaps":["Did not resolve distinct toxin-binding regions structurally","In vivo relevance addressed only later"]},{"year":2016,"claim":"Showed bone-marrow macrophage DARC binds and stabilizes CD82 on hematopoietic stem cells to enforce TGF-β1/Smad3 quiescence, generalizing the DARC-KAI1 senescence axis to stem-cell maintenance.","evidence":"Cd82-/- mice, macrophage ablation, flow cytometry and TGF-β1/Smad3 signaling and cell-cycle assays","pmids":["26996598"],"confidence":"High","gaps":["Direct DARC-CD82 binding interface not structurally defined","Whether chemokine binding influences this interaction unknown"]},{"year":2017,"claim":"Pinpointed the endothelial niche (post-capillary venules, junction-concentrated) where leukocyte adhesion occurs, and showed conformational exposure of the DBP-binding site on immature reticulocytes explains P. vivax tropism.","evidence":"Purpose-built anti-DARC monoclonal antibodies, tissue immunostaining and intravital microscopy; reticulocyte maturation flow cytometry with DBP binding; pancreatic cancer DARC knockdown CXCR2/STAT3 assays","pmids":["28526034","28754683","28214673"],"confidence":"Medium","gaps":["Reticulocyte conformational change inferred without direct structure","CXCR2/STAT3 suppression shown in single cancer model"]},{"year":2018,"claim":"Resolved how endothelial ACKR1 directs migration: it presents neutrophil-derived CXCL2 as a junctional depot enabling unidirectional luminal-to-abluminal neutrophil transmigration.","evidence":"Confocal intravital microscopy of cytokine-stimulated cremaster muscle in ACKR1-KO mice","pmids":["30446388"],"confidence":"High","gaps":["Molecular basis of directionality not fully defined","Generalizability to other chemokines/leukocytes addressed separately"]},{"year":2019,"claim":"Established endothelial DARC as the critical in vivo target of S. aureus leukocidins for lethality, and refined erythroid DARC's conformation-dependent handling of CXCL12.","evidence":"Endothelial conditional DARC-KO mice with toxin and bloodstream infection models; CXCL12/SDF-1 binding assays across erythroid maturation with IL-8/antibody induction","pmids":["30799265","31700087"],"confidence":"High","gaps":["CXCL12 binding consequences for trafficking not established","Conformational switch mechanism inferred indirectly"]},{"year":2021,"claim":"Showed endothelial ACKR1 biases T-cell diapedesis toward the transcellular route at the blood-brain barrier, extending its junctional migratory role beyond neutrophils.","evidence":"RNA-seq, ACKR1 KO in primary brain microvascular endothelial cells under flow, T-cell diapedesis assay","pmids":["34524684"],"confidence":"Medium","gaps":["Single in vitro system","Mechanistic link between ACKR1 and transcellular pathway selection unresolved"]},{"year":2023,"claim":"Provided atomic detail of the sulphated interaction, showing DARC Tyr41-sulphate docks into a charged PvDBP-RII pocket, and defining a growth-inhibitory vaccine epitope.","evidence":"Crystal structure of PvDBP-RII with sulphated DARC peptide, MD simulations, affinity measurements and parasite growth inhibition","pmids":["37336887"],"confidence":"High","gaps":["Full receptor context on intact reticulocytes not captured","Translation to broadly protective vaccine not yet achieved"]},{"year":2024,"claim":"Expanded endothelial ACKR1's pathological roles—FOLR2+ macrophage recruitment in tendon repair and an ACKR1/NF-κB/SPP1 axis driving aortic dissection—and identified anti-ACKR1 autoantibodies mediating endothelial ADCC after COVID-19.","evidence":"Bone marrow chimeras with scRNA-seq/proteomics (tendon); gain/loss-of-function ECs with NF-κB analysis and TAAD mouse model; patient IgG ADCC assays with blocking peptide rescue","pmids":["38714649","39692014","38740432"],"confidence":"Medium","gaps":["Each finding from a single lab/model","Direct versus indirect role of ACKR1 in NF-κB/SPP1 signaling not fully separated","Autoantibody clinical relevance not established"]},{"year":null,"claim":"How ACKR1's non-signaling chemokine binding, transcytosis, junctional presentation, and protein-protein partnerships (KAI1/CD82) are coordinated at the molecular level—and which trafficking machinery executes transcytosis and EV secretion—remains undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of the chemokine-bound endothelial receptor at junctions","Transcytosis and EV-secretion machinery unidentified","Structural basis of the DARC-CD82 interaction unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[4,11,12,14,23,17]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[3,18]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[0,1,9,10]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,27,26]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,16,18]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,2,9,18]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[13,18,21]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,12,14,19,23]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15,25,27]}],"complexes":[],"partners":["CD82","CXCL2","CCL2","CXCL8","CXCL12"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q16570","full_name":"Atypical chemokine receptor 1","aliases":["Duffy antigen receptor for chemokines","Duffy antigen/chemokine receptor","Duffy blood group antigen","Fy glycoprotein","GpFy","Glycoprotein D","Plasmodium vivax receptor"],"length_aa":336,"mass_kda":35.6,"function":"Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Has a promiscuous chemokine-binding profile, interacting with inflammatory chemokines of both the CXC and the CC subfamilies but not with homeostatic chemokines. Acts as a receptor for chemokines including CCL2, CCL5, CCL7, CCL11, CCL13, CCL14, CCL17, CXCL5, CXCL6, IL8/CXCL8, CXCL11, GRO, RANTES, MCP-1 and TARC. May regulate chemokine bioavailability and, consequently, leukocyte recruitment through two distinct mechanisms: when expressed in endothelial cells, it sustains the abluminal to luminal transcytosis of tissue-derived chemokines and their subsequent presentation to circulating leukocytes; when expressed in erythrocytes, serves as blood reservoir of cognate chemokines but also as a chemokine sink, buffering potential surges in plasma chemokine levels (Microbial infection) Acts as a receptor for the malaria parasite Plasmodium vivax (Microbial infection) Acts as a receptor for the malaria parasite Plasmodium knowlesi","subcellular_location":"Early endosome; Recycling endosome; Membrane","url":"https://www.uniprot.org/uniprotkb/Q16570/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ACKR1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ACKR1","total_profiled":1310},"omim":[{"mim_id":"613665","title":"ATYPICAL CHEMOKINE RECEPTOR 1; ACKR1","url":"https://www.omim.org/entry/613665"},{"mim_id":"611862","title":"WHITE BLOOD CELL COUNT QUANTITATIVE TRAIT LOCUS 1; WBCQ1","url":"https://www.omim.org/entry/611862"},{"mim_id":"110700","title":"BLOOD GROUP, DUFFY SYSTEM; FY","url":"https://www.omim.org/entry/110700"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"adipose tissue","ntpm":387.8},{"tissue":"breast","ntpm":337.2}],"url":"https://www.proteinatlas.org/search/ACKR1"},"hgnc":{"alias_symbol":["CCBP1","GPD","Dfy","CD234"],"prev_symbol":["FY","DARC"]},"alphafold":{"accession":"Q16570","domains":[{"cath_id":"1.20.1070.10","chopping":"58-315","consensus_level":"high","plddt":88.2229,"start":58,"end":315}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16570","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16570-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16570-F1-predicted_aligned_error_v6.png","plddt_mean":78.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ACKR1","jax_strain_url":"https://www.jax.org/strain/search?query=ACKR1"},"sequence":{"accession":"Q16570","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16570.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16570/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16570"}},"corpus_meta":[{"pmid":"30446388","id":"PMC_30446388","title":"Distinct Compartmentalization of the Chemokines CXCL1 and CXCL2 and the Atypical Receptor ACKR1 Determine Discrete Stages of Neutrophil Diapedesis.","date":"2018","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30446388","citation_count":286,"is_preprint":false},{"pmid":"7699323","id":"PMC_7699323","title":"The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7699323","citation_count":236,"is_preprint":false},{"pmid":"16862154","id":"PMC_16862154","title":"Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression.","date":"2006","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16862154","citation_count":185,"is_preprint":false},{"pmid":"10961863","id":"PMC_10961863","title":"Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC).","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10961863","citation_count":172,"is_preprint":false},{"pmid":"26996598","id":"PMC_26996598","title":"CD82/KAI1 Maintains the Dormancy of Long-Term Hematopoietic Stem Cells through Interaction with DARC-Expressing Macrophages.","date":"2016","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/26996598","citation_count":135,"is_preprint":false},{"pmid":"28526034","id":"PMC_28526034","title":"Differential DARC/ACKR1 expression distinguishes venular from non-venular endothelial cells in murine tissues.","date":"2017","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/28526034","citation_count":129,"is_preprint":false},{"pmid":"15720550","id":"PMC_15720550","title":"Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC).","date":"2005","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/15720550","citation_count":124,"is_preprint":false},{"pmid":"21743458","id":"PMC_21743458","title":"Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC.","date":"2011","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21743458","citation_count":117,"is_preprint":false},{"pmid":"16394268","id":"PMC_16394268","title":"The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth.","date":"2006","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/16394268","citation_count":109,"is_preprint":false},{"pmid":"20040767","id":"PMC_20040767","title":"Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20040767","citation_count":104,"is_preprint":false},{"pmid":"26320997","id":"PMC_26320997","title":"Staphylococcus aureus Targets the Duffy Antigen Receptor for Chemokines (DARC) to Lyse Erythrocytes.","date":"2015","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/26320997","citation_count":97,"is_preprint":false},{"pmid":"10757794","id":"PMC_10757794","title":"Deletion of the murine Duffy gene (Dfy) reveals that the Duffy receptor is functionally redundant.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10757794","citation_count":91,"is_preprint":false},{"pmid":"24415938","id":"PMC_24415938","title":"Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC.","date":"2014","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/24415938","citation_count":90,"is_preprint":false},{"pmid":"15214968","id":"PMC_15214968","title":"Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis.","date":"2004","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15214968","citation_count":84,"is_preprint":false},{"pmid":"28282382","id":"PMC_28282382","title":"Population genetic analysis of the DARC locus (Duffy) reveals adaptation from standing variation associated with malaria resistance in humans.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28282382","citation_count":81,"is_preprint":false},{"pmid":"13679391","id":"PMC_13679391","title":"A high endothelial venule-expressing promiscuous chemokine receptor DARC can bind inflammatory, but not lymphoid, chemokines and is dispensable for lymphocyte homing under physiological conditions.","date":"2003","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/13679391","citation_count":78,"is_preprint":false},{"pmid":"17073738","id":"PMC_17073738","title":"Throwing light on DARC.","date":"2006","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/17073738","citation_count":70,"is_preprint":false},{"pmid":"24625696","id":"PMC_24625696","title":"DARC shuttles inflammatory chemokines across the blood-brain barrier during autoimmune central nervous system inflammation.","date":"2014","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24625696","citation_count":63,"is_preprint":false},{"pmid":"30944146","id":"PMC_30944146","title":"Atypical Chemokine Receptor 1 (DARC/ACKR1) in Breast Tumors Is Associated with Survival, Circulating Chemokines, Tumor-Infiltrating Immune Cells, and African Ancestry.","date":"2019","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30944146","citation_count":57,"is_preprint":false},{"pmid":"12081195","id":"PMC_12081195","title":"Expression of the duffy antigen/receptor for chemokines (DARC) by the inflamed synovial endothelium.","date":"2002","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12081195","citation_count":56,"is_preprint":false},{"pmid":"16046070","id":"PMC_16046070","title":"A structural model of a seven-transmembrane helix receptor: the Duffy antigen/receptor for chemokine (DARC).","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16046070","citation_count":56,"is_preprint":false},{"pmid":"11322957","id":"PMC_11322957","title":"Duffy-null promoter heterozygosity reduces DARC expression and abrogates adhesion of the P. vivax ligand required for blood-stage infection.","date":"2001","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11322957","citation_count":53,"is_preprint":false},{"pmid":"18710383","id":"PMC_18710383","title":"Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean.","date":"2008","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/18710383","citation_count":50,"is_preprint":false},{"pmid":"22207676","id":"PMC_22207676","title":"The association between a Darc gene polymorphism and clinical outcomes in African American patients with acute lung injury.","date":"2011","source":"Chest","url":"https://pubmed.ncbi.nlm.nih.gov/22207676","citation_count":50,"is_preprint":false},{"pmid":"12087071","id":"PMC_12087071","title":"The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white?","date":"2002","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12087071","citation_count":50,"is_preprint":false},{"pmid":"22221512","id":"PMC_22221512","title":"Construction of an artificial cell membrane anchor using DARC as a fitting for artificial extracellular functionalities of eukaryotic cells.","date":"2012","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/22221512","citation_count":50,"is_preprint":false},{"pmid":"9921412","id":"PMC_9921412","title":"Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC).","date":"1998","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/9921412","citation_count":50,"is_preprint":false},{"pmid":"9070443","id":"PMC_9070443","title":"IL-8 single-chain homodimers and heterodimers: interactions with chemokine receptors CXCR1, CXCR2, and DARC.","date":"1997","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/9070443","citation_count":50,"is_preprint":false},{"pmid":"34102318","id":"PMC_34102318","title":"Detecting retinal cell stress and apoptosis with DARC: Progression from lab to clinic.","date":"2021","source":"Progress in retinal and eye research","url":"https://pubmed.ncbi.nlm.nih.gov/34102318","citation_count":47,"is_preprint":false},{"pmid":"19499525","id":"PMC_19499525","title":"DARC on RBC limits lung injury by balancing compartmental distribution of CXC chemokines.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19499525","citation_count":44,"is_preprint":false},{"pmid":"17416748","id":"PMC_17416748","title":"Identification of mouse Duffy antigen receptor for chemokines (Darc) as a BMD QTL gene.","date":"2007","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/17416748","citation_count":41,"is_preprint":false},{"pmid":"21151196","id":"PMC_21151196","title":"DARC and D6: silent partners in chemokine regulation?","date":"2010","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21151196","citation_count":39,"is_preprint":false},{"pmid":"12698093","id":"PMC_12698093","title":"When renal allografts turn DARC.","date":"2003","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/12698093","citation_count":39,"is_preprint":false},{"pmid":"28754683","id":"PMC_28754683","title":"DARC extracellular domain remodeling in maturating reticulocytes explains Plasmodium vivax tropism.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28754683","citation_count":39,"is_preprint":false},{"pmid":"30592023","id":"PMC_30592023","title":"The Duffy antigen receptor for chemokines, ACKR1,- 'Jeanne DARC' of benign neutropenia.","date":"2018","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/30592023","citation_count":37,"is_preprint":false},{"pmid":"15572394","id":"PMC_15572394","title":"Expression of DARC, CXCR3 and CCR5 in giant cell arteritis.","date":"2004","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15572394","citation_count":37,"is_preprint":false},{"pmid":"37006247","id":"PMC_37006247","title":"Prospects for targeting ACKR1 in cancer and other diseases.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37006247","citation_count":36,"is_preprint":false},{"pmid":"30799265","id":"PMC_30799265","title":"Staphylococcus aureus Leukocidins Target Endothelial DARC to Cause Lethality in Mice.","date":"2019","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/30799265","citation_count":32,"is_preprint":false},{"pmid":"22082243","id":"PMC_22082243","title":"DARC alleles and Duffy phenotypes in African Americans.","date":"2011","source":"Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/22082243","citation_count":30,"is_preprint":false},{"pmid":"30218021","id":"PMC_30218021","title":"Susceptibility to Plasmodium vivax malaria associated with DARC (Duffy antigen) polymorphisms is influenced by the time of exposure to malaria.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30218021","citation_count":30,"is_preprint":false},{"pmid":"21878684","id":"PMC_21878684","title":"Species-specific features of DARC, the primate receptor for Plasmodium vivax and Plasmodium knowlesi.","date":"2011","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/21878684","citation_count":29,"is_preprint":false},{"pmid":"19454340","id":"PMC_19454340","title":"Expression of Duffy antigen receptor for chemokines (DARC) has no effect on HIV-1 acquisition or progression to AIDS in African Americans.","date":"2009","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/19454340","citation_count":29,"is_preprint":false},{"pmid":"34524684","id":"PMC_34524684","title":"ACKR1 favors transcellular over paracellular T-cell diapedesis across the blood-brain barrier in neuroinflammation in vitro.","date":"2021","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34524684","citation_count":28,"is_preprint":false},{"pmid":"28214673","id":"PMC_28214673","title":"Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.","date":"2017","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/28214673","citation_count":28,"is_preprint":false},{"pmid":"28698207","id":"PMC_28698207","title":"Strict tropism for CD71+/CD234+ human reticulocytes limits the zoonotic potential of Plasmodium cynomolgi.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28698207","citation_count":27,"is_preprint":false},{"pmid":"38714649","id":"PMC_38714649","title":"Multi-omics analysis of human tendon adhesion reveals that ACKR1-regulated macrophage migration is involved in regeneration.","date":"2024","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/38714649","citation_count":25,"is_preprint":false},{"pmid":"17955335","id":"PMC_17955335","title":"Duffy antigen/receptor for chemokines (DARC) attenuates angiogenesis by causing senescence in endothelial cells.","date":"2007","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17955335","citation_count":24,"is_preprint":false},{"pmid":"23168236","id":"PMC_23168236","title":"DARC (Duffy) and BCAM (Lutheran) reduced expression in thyroid cancer.","date":"2012","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/23168236","citation_count":23,"is_preprint":false},{"pmid":"24260134","id":"PMC_24260134","title":"Effect of genetic variants in two chemokine decoy receptor genes, DARC and CCBP2, on metastatic potential of breast cancer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24260134","citation_count":23,"is_preprint":false},{"pmid":"20664684","id":"PMC_20664684","title":"Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC).","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20664684","citation_count":22,"is_preprint":false},{"pmid":"30245840","id":"PMC_30245840","title":"Long-range haplotype analysis of the malaria parasite receptor gene ACKR1 in an East-African population.","date":"2018","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/30245840","citation_count":20,"is_preprint":false},{"pmid":"26473357","id":"PMC_26473357","title":"Distinct Transcript Isoforms of the Atypical Chemokine Receptor 1 (ACKR1)/Duffy Antigen Receptor for Chemokines (DARC) Gene Are Expressed in Lymphoblasts and Altered Isoform Levels Are Associated with Genetic Ancestry and the Duffy-Null Allele.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26473357","citation_count":20,"is_preprint":false},{"pmid":"39692014","id":"PMC_39692014","title":"ACKR1hiECs Promote Aortic Dissection Through Adjusting Macrophage Behavior.","date":"2024","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/39692014","citation_count":18,"is_preprint":false},{"pmid":"26126123","id":"PMC_26126123","title":"DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites.","date":"2015","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26126123","citation_count":18,"is_preprint":false},{"pmid":"21441947","id":"PMC_21441947","title":"Erythrocyte Duffy antigen receptor for chemokines (DARC): diagnostic and therapeutic implications in atherosclerotic cardiovascular disease.","date":"2011","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/21441947","citation_count":17,"is_preprint":false},{"pmid":"24710306","id":"PMC_24710306","title":"Duffy antigen receptor for chemokine (DARC) polymorphisms and its involvement in acquisition of inhibitory anti-duffy binding protein II (DBPII) immunity.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24710306","citation_count":17,"is_preprint":false},{"pmid":"36497078","id":"PMC_36497078","title":"The DARC Side of Inflamm-Aging: Duffy Antigen Receptor for Chemokines (DARC/ACKR1) as a Potential Biomarker of Aging, Immunosenescence, and Breast Oncogenesis among High-Risk Subpopulations.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36497078","citation_count":16,"is_preprint":false},{"pmid":"20596779","id":"PMC_20596779","title":"The Duffy Antigen/Receptor for Chemokines (DARC) and prostate-cancer risk among Jamaican men.","date":"2011","source":"Journal of immigrant and minority health","url":"https://pubmed.ncbi.nlm.nih.gov/20596779","citation_count":16,"is_preprint":false},{"pmid":"39764562","id":"PMC_39764562","title":"PDPN+ cancer-associated fibroblasts enhance gastric cancer angiogenesis via AKT/NF-κB activation and the CCL2-ACKR1 axis.","date":"2025","source":"MedComm","url":"https://pubmed.ncbi.nlm.nih.gov/39764562","citation_count":15,"is_preprint":false},{"pmid":"26181386","id":"PMC_26181386","title":"DARC 2.0: Improved Docking and Virtual Screening at Protein Interaction Sites.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26181386","citation_count":15,"is_preprint":false},{"pmid":"16807107","id":"PMC_16807107","title":"The DARC conspiracy--virus invasion tactics.","date":"2006","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16807107","citation_count":15,"is_preprint":false},{"pmid":"19519483","id":"PMC_19519483","title":"In silico studies on DARC.","date":"2009","source":"Infectious disorders drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/19519483","citation_count":14,"is_preprint":false},{"pmid":"24399209","id":"PMC_24399209","title":"Distribution of Duffy Antigen Receptor for Chemokines (DARC) and Risk of Prostate Cancer in Barbados, West Indies.","date":"2015","source":"Journal of immigrant and minority health","url":"https://pubmed.ncbi.nlm.nih.gov/24399209","citation_count":14,"is_preprint":false},{"pmid":"37153544","id":"PMC_37153544","title":"Endothelial ACKR1 is induced by neutrophil contact and down-regulated by secretion in extracellular vesicles.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37153544","citation_count":13,"is_preprint":false},{"pmid":"37336887","id":"PMC_37336887","title":"Structural basis for DARC binding in reticulocyte invasion by Plasmodium vivax.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37336887","citation_count":13,"is_preprint":false},{"pmid":"29341885","id":"PMC_29341885","title":"Deletion of the Duffy antigen receptor for chemokines (DARC) promotes insulin resistance and adipose tissue inflammation during high fat feeding.","date":"2018","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29341885","citation_count":13,"is_preprint":false},{"pmid":"18621004","id":"PMC_18621004","title":"HIV and chemokine binding to red blood cells--DARC matters.","date":"2008","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/18621004","citation_count":12,"is_preprint":false},{"pmid":"21088296","id":"PMC_21088296","title":"Activation state of alpha4beta1 integrin on sickle red blood cells is linked to the duffy antigen receptor for chemokines (DARC) expression.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21088296","citation_count":12,"is_preprint":false},{"pmid":"20196090","id":"PMC_20196090","title":"Synthesis of disulfated peptides corresponding to the N-terminus of chemokines receptors CXCR6 (CXCR6 1-20) and DARC (DARC 8-42) using a sulfate-protecting group strategy.","date":"2010","source":"Journal of peptide science : an official publication of the European Peptide Society","url":"https://pubmed.ncbi.nlm.nih.gov/20196090","citation_count":12,"is_preprint":false},{"pmid":"28337061","id":"PMC_28337061","title":"An introduction to DARC technology.","date":"2016","source":"Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society","url":"https://pubmed.ncbi.nlm.nih.gov/28337061","citation_count":11,"is_preprint":false},{"pmid":"20655787","id":"PMC_20655787","title":"Multiple interests in structural models of DARC transmembrane protein.","date":"2010","source":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","url":"https://pubmed.ncbi.nlm.nih.gov/20655787","citation_count":11,"is_preprint":false},{"pmid":"16959609","id":"PMC_16959609","title":"The DARC side of metastasis: shining a light on KAI1-mediated metastasis suppression in the vascular tunnel.","date":"2006","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/16959609","citation_count":11,"is_preprint":false},{"pmid":"38039514","id":"PMC_38039514","title":"Clinical and immunological features in ACKR1/DARC-associated neutropenia.","date":"2024","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/38039514","citation_count":10,"is_preprint":false},{"pmid":"38151287","id":"PMC_38151287","title":"Single-cell Transcriptomic Analysis Reveals an Immunosuppressive Network Between POSTN CAFs and ACKR1 ECs in TKI-resistant Lung Cancer.","date":"2024","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/38151287","citation_count":10,"is_preprint":false},{"pmid":"32015389","id":"PMC_32015389","title":"Deep Analysis of Residue Constraints (DARC): identifying determinants of protein functional specificity.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32015389","citation_count":10,"is_preprint":false},{"pmid":"26096170","id":"PMC_26096170","title":"Expression of Duffy antigen receptor for chemokines (DARC) is down-regulated in colorectal cancer.","date":"2015","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/26096170","citation_count":10,"is_preprint":false},{"pmid":"32110191","id":"PMC_32110191","title":"Defining Blood Group Gene Reference Alleles by Long-Read Sequencing: Proof of Concept in the ACKR1 Gene Encoding the Duffy Antigens.","date":"2019","source":"Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie","url":"https://pubmed.ncbi.nlm.nih.gov/32110191","citation_count":10,"is_preprint":false},{"pmid":"30972057","id":"PMC_30972057","title":"Neutrophil Effector Functions Are Not Impaired in Duffy Antigen Receptor for Chemokines (DARC)-Null Black South Africans.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30972057","citation_count":10,"is_preprint":false},{"pmid":"32688055","id":"PMC_32688055","title":"ACKR1 Alleles at 5.6 kb in a Well-Characterized Renewable US Food and Drug Administration (FDA) Reference Panel for Standardization of Blood Group Genotyping.","date":"2020","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/32688055","citation_count":9,"is_preprint":false},{"pmid":"22395823","id":"PMC_22395823","title":"Molecular evolution of a malaria resistance gene (DARC) in primates.","date":"2012","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/22395823","citation_count":9,"is_preprint":false},{"pmid":"31700087","id":"PMC_31700087","title":"Differential interaction between DARC and SDF-1 on erythrocytes and their precursors.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31700087","citation_count":8,"is_preprint":false},{"pmid":"30970632","id":"PMC_30970632","title":"Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study.","date":"2019","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/30970632","citation_count":8,"is_preprint":false},{"pmid":"19643012","id":"PMC_19643012","title":"CCR5 signalling, but not DARC or D6 regulatory, chemokine receptors are targeted by herpesvirus U83A chemokine which delays receptor internalisation via diversion to a caveolin-linked pathway.","date":"2009","source":"Journal of inflammation (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19643012","citation_count":8,"is_preprint":false},{"pmid":"30928426","id":"PMC_30928426","title":"Duffy antigen receptor for chemokines (DARC) and susceptibility to Plasmodium vivax malaria.","date":"2019","source":"Parasitology international","url":"https://pubmed.ncbi.nlm.nih.gov/30928426","citation_count":7,"is_preprint":false},{"pmid":"17236552","id":"PMC_17236552","title":"[Downregulation of Duffy antigen receptor for chemokine (DARC) is associated with lymph node metastasis in human breast cancer].","date":"2006","source":"Zhonghua zhong liu za zhi [Chinese journal of oncology]","url":"https://pubmed.ncbi.nlm.nih.gov/17236552","citation_count":7,"is_preprint":false},{"pmid":"25706384","id":"PMC_25706384","title":"Studies of a murine monoclonal antibody directed against DARC: reappraisal of its specificity.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25706384","citation_count":6,"is_preprint":false},{"pmid":"19559488","id":"PMC_19559488","title":"Characterization and transcriptional analysis of the promoter region of the Duffy blood group, chemokine receptor (DARC) gene in cattle.","date":"2009","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/19559488","citation_count":6,"is_preprint":false},{"pmid":"22009674","id":"PMC_22009674","title":"The DARC site: a database of aligned ribosomal complexes.","date":"2011","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/22009674","citation_count":6,"is_preprint":false},{"pmid":"21156192","id":"PMC_21156192","title":"A Duffy antigen receptor for chemokines (DARC) polymorphism that determines pro-fibrotic chemokine serum concentrations is not directly associated with severity of hepatitis C infection.","date":"2010","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21156192","citation_count":6,"is_preprint":false},{"pmid":"33211774","id":"PMC_33211774","title":"The DARC-null trait is associated with moderate modulation of NK cell profiles and unaltered cytolytic T cell profiles in black South Africans.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33211774","citation_count":5,"is_preprint":false},{"pmid":"30211170","id":"PMC_30211170","title":"Engagement Rules That Underpin DBL-DARC Interactions for Ingress of Plasmodium knowlesi and Plasmodium vivax Into Human Erythrocytes.","date":"2018","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/30211170","citation_count":5,"is_preprint":false},{"pmid":"11446431","id":"PMC_11446431","title":"Duffy antigen/receptor for chemokines (DARC): genotypes in Ashkenazi and non-Ashkenazi Jews in Israel.","date":"2001","source":"Human biology","url":"https://pubmed.ncbi.nlm.nih.gov/11446431","citation_count":5,"is_preprint":false},{"pmid":"40380233","id":"PMC_40380233","title":"Single-cell transcriptomic analysis deciphers the inflammatory microenvironment characterized by CXCL9+ fibroblasts and ACKR1+ endothelial cells in immune-related myocarditis.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40380233","citation_count":4,"is_preprint":false},{"pmid":"38740432","id":"PMC_38740432","title":"Inflammatory risk contributes to post-COVID endothelial dysfunction through anti-ACKR1 autoantibody.","date":"2024","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/38740432","citation_count":4,"is_preprint":false},{"pmid":"40853589","id":"PMC_40853589","title":"Investigating the interaction of ACKR1 and c-Myc in the breast carcinoma tumor microenvironment modulation.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40853589","citation_count":4,"is_preprint":false},{"pmid":"27376530","id":"PMC_27376530","title":"Potential Role of DARC-Chemokine Interaction in the Recruitment of Osteoclast Precursors in Response to Bacterial Lipopolysaccharide Challenge.","date":"2016","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/27376530","citation_count":4,"is_preprint":false},{"pmid":"21784153","id":"PMC_21784153","title":"Evidence that erythrocyte DARC-positive phenotype can affect the GVHD occurrence after HLA-identical sibling HSCT.","date":"2011","source":"Transplant immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21784153","citation_count":4,"is_preprint":false},{"pmid":"36376015","id":"PMC_36376015","title":"Ancestry, ACKR1 and leucopenia in patients with systemic lupus erythematosus.","date":"2022","source":"Lupus science & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36376015","citation_count":3,"is_preprint":false},{"pmid":"27968956","id":"PMC_27968956","title":"A genetic marker of the ACKR1 gene is present in patients with Type II congenital smell loss who have type I hyposmia and hypogeusia.","date":"2015","source":"American journal of otolaryngology","url":"https://pubmed.ncbi.nlm.nih.gov/27968956","citation_count":3,"is_preprint":false},{"pmid":"34039276","id":"PMC_34039276","title":"Cataloguing experimentally confirmed 80.7 kb-long ACKR1 haplotypes from the 1000 Genomes Project database.","date":"2021","source":"BMC bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/34039276","citation_count":3,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49887,"output_tokens":7542,"usd":0.131395,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16775,"output_tokens":5711,"usd":0.113325,"stage2_stop_reason":"end_turn"},"total_usd":0.24472,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"DARC (ACKR1) expressed on erythrocytes internalizes radiolabeled chemokine ligands upon transfection, whereas endothelial DARC expression is maintained in Duffy-negative individuals who lack erythrocyte DARC, indicating tissue-specific regulatory mechanisms for DARC expression.\",\n      \"method\": \"Radiolabeled ligand internalization assay, immunohistochemistry, biochemical and molecular biological analysis of tissues from Duffy-negative individuals\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (radiolabeled internalization, IHC, biochemistry, molecular biology), replicated across tissues, foundational study\",\n      \"pmids\": [\"7699323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"DARC knockout mice lacking both erythroid and endothelial DARC show exaggerated inflammatory infiltrates in lung and liver following LPS challenge, and erythrocytes from null mice lack CXC and CC chemokine-binding activity, demonstrating DARC functions as a chemokine sink that modulates inflammation intensity.\",\n      \"method\": \"Targeted gene disruption (knockout mice), LPS challenge model, hematological analysis, chemokine binding assay on erythrocytes\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotype, multiple readouts, replicated concept across multiple labs\",\n      \"pmids\": [\"10961863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Deletion of murine Dfy (DARC ortholog) reduces neutrophil migration into the peritoneal cavity and intestines/lungs following LPS/thioglycolate challenge, establishing a role for DARC in the neutrophil migratory process, though the receptor appears functionally redundant for most developmental and immune parameters.\",\n      \"method\": \"Targeted gene deletion (Dfy−/− mice), peritoneal inflammation models (LPS and thioglycolate), histological analysis of neutrophil recruitment\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotype, multiple inflammation models, replicated in same paper\",\n      \"pmids\": [\"10757794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"DARC expressed on high endothelial venules (HEV) selectively binds pro-inflammatory chemokines (CXCL1, CXCL5, CCL2, CCL5, CCL7) but not lymphoid chemokines (CCL21, CCL19, CXCL12, CXCL13); DARC-bound CCL2 failed to induce Ca2+ elevation in CCR2B-expressing cells, indicating DARC down-regulates pro-inflammatory chemokine activity upon binding without G-protein signaling.\",\n      \"method\": \"Competitive binding experiments with 20 chemokines, cytosolic Ca2+ elevation assay, targeted gene disruption, lymphocyte trafficking assay\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro binding assays with functional readout (Ca2+ signaling), KO mice, multiple chemokines tested\",\n      \"pmids\": [\"13679391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"DARC tyrosines 30 and 41 are sulphated; sulphated tyrosine 41 is essential for binding of P. vivax Duffy binding protein (PvDBP) and P. knowlesi (PkDaBP), and participates in association with chemokines MCP-1, RANTES, and MGSA but not IL-8; sulphated tyrosine 30 is required for IL-8 binding; a soluble sulphated N-terminal DARC domain blocks PvDBP/PkDaBP binding to RBCs with IC50 ~5 nM.\",\n      \"method\": \"Tyrosine-to-phenylalanine mutagenesis, cell-based binding assays, soluble peptide inhibition assay\",\n      \"journal\": \"Molecular microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of specific residues with functional binding readouts, multiple chemokine ligands tested, inhibition experiments\",\n      \"pmids\": [\"15720550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"DARC on vascular endothelium interacts directly with KAI1 (CD82) on tumor cells; this interaction leads to inhibition of tumor cell proliferation, induction of senescence, and modulation of TBX2 and p21 expression; DARC knockout mice showed significantly compromised KAI1-mediated metastasis suppression.\",\n      \"method\": \"Yeast two-hybrid screen, DARC knockout mouse metastasis model, cell proliferation assays, gene expression analysis\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — yeast two-hybrid identification plus in vivo KO validation, multiple cellular readouts, mechanistic pathway placement\",\n      \"pmids\": [\"16862154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"DARC on erythrocytes clears angiogenic CXC chemokines (produced by prostate cancer cells) in vitro, reducing endothelial cell chemotaxis; in DARC-deficient mice bearing prostate tumors, intra-tumor angiogenic chemokine concentrations are elevated, tumor vessel density is increased, and tumor growth is greatly augmented.\",\n      \"method\": \"In vitro chemokine clearance assay with wild-type vs. DARC-deficient erythrocytes, transgenic prostate cancer model in DARC KO mice, ELISA, vessel density quantification\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro functional assay plus in vivo KO model with multiple orthogonal readouts\",\n      \"pmids\": [\"16394268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"DARC on endothelial cells attenuates angiogenesis by inducing cellular senescence; in DARC-expressing HCEC cells, capillary formation was initially enhanced then attenuated with cells undergoing senescence, while blocking DARC's N-terminal chemokine-binding domain with anti-Fy6 antibody or adding excess IL-8 increased capillary formation; DARC knockout mice showed more capillary formation in Matrigel plugs.\",\n      \"method\": \"In vitro Matrigel angiogenesis assay, in vivo Matrigel plug assay in DARC KO mice, anti-DARC antibody blocking, IL-8 competition\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mice plus in vitro assays with blocking antibody, single lab\",\n      \"pmids\": [\"17955335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"DARC (Darc) regulates bone mineral density (BMD) negatively by promoting osteoclast formation; anti-DARC antibody blocked multinucleated osteoclast formation in vitro; DARC from a high-BMD strain binds chemokines (known to regulate osteoclast formation) with reduced affinity compared to low-BMD strain DARC.\",\n      \"method\": \"QTL mapping, Darc knockout skeletal phenotyping, in vitro osteoclast formation assay with antibody blockade, chemokine binding affinity comparison\",\n      \"journal\": \"Genome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO phenotype plus in vitro antibody blocking assay plus binding affinity comparison, single lab\",\n      \"pmids\": [\"17416748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DARC on red blood cells (RBCs) sequesters CXCL1 from plasma; in DARC-deficient mice, LPS-induced PMN migration into alveolar space was elevated >2-fold with increased alveolar CXCL1 and CXCL2/3, while PMN adhesion to endothelium and interstitial space was reduced; DARC on non-hematopoietic cells had only minor effects in this model.\",\n      \"method\": \"Darc−/− mice, LPS-induced acute lung injury model, bone marrow chimeras distinguishing hematopoietic vs. endothelial DARC, ELISA, flow cytometry\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — bone marrow chimera experiments separating hematopoietic vs. non-hematopoietic DARC, KO mice, multiple chemokine readouts\",\n      \"pmids\": [\"19499525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DARC rs12075 (Asp42Gly) non-synonymous polymorphism is a major regulator of erythrocyte DARC-mediated cytokine binding, accounting for ~20% of variability in serum MCP-1 and also regulating IL-8 and RANTES concentrations; clotting and exogenous heparan sulfate release chemokines from DARC, identifying two mechanisms for reservoir chemokine release.\",\n      \"method\": \"Genome-wide association study (n=9598), family-based genetic linkage, quantitative immunoflow cytometry, ex vivo chemokine release assays with heparan sulfate/clotting\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — large GWAS plus ex vivo functional release assays, but functional mechanism inferred from genetics and ex vivo rather than direct molecular reconstitution\",\n      \"pmids\": [\"20040767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"P. vivax Duffy-binding protein RII (RII-PvDBP) dimerization is required for and driven by DARC receptor engagement; crystallographic, solution, and functional studies show that receptor binding induces dimerization; dimerization is required for red blood cell binding and accounts for action of naturally acquired blocking antibodies.\",\n      \"method\": \"X-ray crystallography, solution studies, functional RBC binding assays, antibody blocking experiments\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with solution and functional studies, multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"21743458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The DARC N-terminal ectodomain forms an amphipathic helix upon PvDBP-RII binding; crystal structures reveal two DBP-RII molecules sandwiching one or two DARC ectodomains creating heterotrimer/heterotetramer architectures; point mutations of DARC contact residues result in complete loss of RBC binding by DBP-RII; isothermal titration calorimetry shows multi-step binding pathway.\",\n      \"method\": \"NMR epitope mapping, X-ray crystallography (two crystal structures), isothermal titration calorimetry, site-directed mutagenesis, RBC binding assays\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR plus X-ray crystallography plus ITC plus mutagenesis plus functional binding assays in a single rigorous study\",\n      \"pmids\": [\"24415938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Endothelial DARC mediates abluminal-to-luminal transcytosis of inflammatory chemokines across the blood-brain barrier; erythrocyte DARC functions as a chemokine reservoir determining plasma chemokine levels; endothelial DARC (not erythrocyte DARC) is required for full EAE pathogenesis as shown by bone marrow chimera experiments.\",\n      \"method\": \"In vitro BBB model, Darc−/− mice in EAE model, bone marrow chimeras separating erythrocyte vs. endothelial DARC, chemokine transcytosis assay\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — bone marrow chimera experiments separating cell-type specific functions, in vitro transcytosis assay, in vivo EAE model with multiple readouts\",\n      \"pmids\": [\"24625696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"S. aureus hemolytic leukocidins LukED and HlgAB use DARC as their receptor on erythrocytes to mediate lysis; HlgA and LukE bind directly to DARC through different regions; DARC expression level directly correlates with susceptibility to toxin-mediated lysis; DARC overexpression is sufficient to render non-erythroid cells susceptible; LukED and HlgAB support S. aureus hemoglobin acquisition in a DARC-dependent manner.\",\n      \"method\": \"Human erythrocyte DARC polymorphism analysis, DARC overexpression in non-erythroid cells, direct binding assays, hemolysis assays, bacterial growth assays\",\n      \"journal\": \"Cell host & microbe\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding assays, overexpression sufficiency, natural human variants used, multiple functional readouts\",\n      \"pmids\": [\"26320997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DARC on bone marrow macrophages (DARC+ BM macrophages) binds CD82/KAI1 on LT-HSCs and stabilizes CD82 surface expression, promoting TGF-β1/Smad3-mediated CDK inhibitor induction and cell-cycle inhibition; ablation of DARC+ BM macrophages decreased surface CD82 on LT-HSCs, causing cell-cycle entry and differentiation.\",\n      \"method\": \"Cd82−/− mice, macrophage ablation experiments, flow cytometry, TGF-β1/Smad3 signaling analysis, cell cycle assays\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mice, macrophage ablation loss-of-function, signaling pathway identification, multiple cell biological readouts\",\n      \"pmids\": [\"26996598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DARC (ACKR1) is exquisitely restricted to post-capillary and small collecting venules (not arteries, arterioles, capillaries, veins, or lymphatics) in all murine tissues; DARC is concentrated at endothelial cell-cell junctions; adhesive leukocyte-endothelial interactions are restricted to DARC+ venules as shown by intravital microscopy.\",\n      \"method\": \"Anti-mouse DARC monoclonal antibody generation, immunostaining of murine tissues, intravital microscopy, single-cell suspension analysis\",\n      \"journal\": \"BMC biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — purpose-built monoclonal antibody, multiple tissue types, intravital microscopy confirming functional correlation with leukocyte adhesion\",\n      \"pmids\": [\"28526034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DARC extracellular domain conformation changes during reticulocyte maturation; although total DARC protein is constant throughout maturation, selective exposure of the DBP-binding site within DARC on CD71high/RNAhigh immature reticulocytes (not mature erythrocytes) explains P. vivax tropism for immature reticulocytes.\",\n      \"method\": \"CD71/RNA flow cytometry of reticulocyte populations, recombinant DBP binding assays, anti-DARC monoclonal antibody binding assays across reticulocyte maturation stages\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional binding assays across differentiation stages, single lab, mechanism inferred from conformational change without direct structural data\",\n      \"pmids\": [\"28754683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ACKR1 is enriched within endothelial junctions of venular walls and presents CXCL2 (produced by transmigrating neutrophils) as a junctional chemokine depot; ACKR1-presented CXCL2 enables efficient unidirectional luminal-to-abluminal neutrophil migration through EC junctions; this pro-migratory activity of CXCL2 depends on ACKR1.\",\n      \"method\": \"Confocal intravital microscopy of cytokine-stimulated mouse cremaster muscles, ACKR1 knockout mice, neutrophil emigration analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo intravital microscopy with KO mice, defined chemokine and receptor, specific directional migration phenotype\",\n      \"pmids\": [\"30446388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DARC on endothelial cells is the critical target for S. aureus LukED and HlgAB leukocidin-mediated lethality in mice; these toxins injure primary human endothelial cells in a DARC-dependent manner; mice with DARC-deficient endothelial cells are resistant to toxin-mediated lethality and show reduced tissue damage during bloodstream infection.\",\n      \"method\": \"DARC-deficient endothelial cell mice (conditional KO), toxin challenge experiments, primary human endothelial cell injury assays, S. aureus bloodstream infection model\",\n      \"journal\": \"Cell host & microbe\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional endothelial cell-specific KO mice, human cell validation, both toxin challenge and infection models\",\n      \"pmids\": [\"30799265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DARC on erythrocyte progenitors binds SDF-1 (CXCL12) in a DARC-dependent and conformation-dependent manner; SDF-1 binding is absent on mature erythrocytes due to conformational changes during erythroid development; SDF-1 binding to mature erythrocytes can be induced by pre-treating with IL-8 or specific anti-DARC antibodies that alter DARC conformation.\",\n      \"method\": \"Flow cytometry binding assays with recombinant SDF-1, anti-DARC antibody competition, IL-8 pre-treatment experiments on erythrocytes at different maturation stages\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding assays with induction/competition experiments, single lab, functional implications inferred\",\n      \"pmids\": [\"31700087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ACKR1 upregulation in brain microvascular endothelial cells favors transcellular over paracellular T-cell diapedesis across the blood-brain barrier; loss of endothelial ACKR1 reduced transcellular T-cell diapedesis under physiological flow in vitro; ACKR1 is upregulated in venular endothelial cells during EAE.\",\n      \"method\": \"RNA-seq transcriptome profiling of pMBMECs, ACKR1 protein upregulation confirmation, ACKR1 KO in pMBMECs under flow conditions, T-cell diapedesis assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO loss-of-function in vitro under physiological flow, RNA-seq plus protein validation, single lab\",\n      \"pmids\": [\"34524684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Endothelial ACKR1 expression is induced by contact with neutrophils (not other blood cells) and is regulated by NF-κB; upon removal of blood, ACKR1 protein is rapidly secreted via extracellular vesicles; endogenous ACKR1 does not signal (no response to IL-8 or CXCL1 stimulation confirmed).\",\n      \"method\": \"Primary human lung microvascular endothelial cell culture with whole blood/isolated cell fractions, NF-κB inhibition, extracellular vesicle characterization, IL-8/CXCL1 stimulation signaling assay\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro methods, NF-κB regulation and EV secretion identified, negative signaling result confirmed, single lab\",\n      \"pmids\": [\"37153544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Crystal structure of PvDBP-RII bound to sulphated DARC peptide shows that sulphate on DARC tyrosine 41 binds to a charged pocket on PvDBP-RII; molecular dynamics simulations, affinity measurements, and parasite growth-inhibition experiments confirm importance of this sulphated interaction; the epitope for vaccine-elicited growth-inhibitory antibody DB1 is revealed.\",\n      \"method\": \"X-ray crystallography, molecular dynamics simulations, affinity measurements, parasite growth-inhibition experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus molecular dynamics plus affinity measurements plus functional parasite growth inhibition in a single rigorous study\",\n      \"pmids\": [\"37336887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ACKR1 in endothelial cells regulates FOLR2+ macrophage migration to injured peritendinous sites; Ackr1−/− bone marrow chimeras showed a decline of FOLR2+ macrophages at the injury site, demonstrating ACKR1-regulated macrophage recruitment is involved in tendon adhesion/regeneration.\",\n      \"method\": \"Single-cell RNA sequencing, bone marrow transplantation chimeras (Lysm-Cre;R26RtdTomato→Ackr1−/− mice), proteomics, in vitro experiments with human cells\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bone marrow chimera loss-of-function with defined macrophage subset readout, supported by scRNA-seq and proteomics, single lab\",\n      \"pmids\": [\"38714649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Endothelial cells with high ACKR1 expression (ACKR1hi ECs) promote aortic dissection (TAAD) through the ACKR1/NF-κB/SPP1 signaling pathway; ACKR1 knockdown suppressed NF-κB signaling and SPP1 expression, reducing macrophage migration and proinflammatory polarization; ACKR1 overexpression exacerbated TAAD; the drug amikacin targets this pathway.\",\n      \"method\": \"Single-cell transcriptomics, gain- and loss-of-function ACKR1 modulation in ECs, NF-κB pathway analysis, macrophage migration/polarization assays, in vivo TAAD mouse model, molecular docking\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain and loss-of-function experiments with defined signaling pathway, in vivo mouse model, single lab\",\n      \"pmids\": [\"39692014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"DARC on Duffy-positive sickle reticulocytes (SRe) maintains α4β1 integrin in a higher chemokine-sensitive affinity state; IL-8 increased Duffy-positive SRe adhesion to VCAM-1 and fibronectin but not Duffy-negative SRe; IL-8 induced α4β1 clustering (not affinity change) in Duffy-positive SRe, demonstrating DARC-dependent modulation of integrin activation state.\",\n      \"method\": \"Static adhesion assays, flow cytometry with conformation-sensitive anti-β1 antibody, immunofluorescence microscopy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — comparison of Duffy-positive vs. negative SRe with conformation-sensitive antibody and multiple functional readouts, single lab\",\n      \"pmids\": [\"21088296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DARC expressed in pancreatic cancer cells inhibits CXCR2 signaling and downstream STAT3 activation; DARC knockdown significantly increased cell proliferation in high-DARC cells by activating STAT3; CXCR2-induced STAT3 activation promotes cell cycle progression, inhibits apoptosis, induces angiogenesis, and enhances invasiveness, all of which DARC suppresses by down-regulating CXCR2 signaling.\",\n      \"method\": \"DARC knockdown, CXCR2 knockdown, STAT3 activation assay (EMSA), cell proliferation assays, apoptosis assays, clinical specimen analysis\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown experiments with defined signaling pathway readout (STAT3/EMSA), single lab\",\n      \"pmids\": [\"28214673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Anti-ACKR1 autoantibodies from COVID-19 survivors target the N-terminal extracellular domain of ACKR1 on endothelial cells and mediate antibody-dependent cellular cytotoxicity (ADCC) via PBMCs; blocking peptide or liposome ACKR1 recombinant protein alleviated ADCC; purified IgG did not directly trigger apoptosis or increase barrier permeability.\",\n      \"method\": \"Purified IgG from patient plasma, ADCC assay, ACKR1 blocking peptide/recombinant protein, human vein endothelial cell assays, flow cytometry\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — purified IgG functional assays with blocking peptide rescue, multiple readouts, single lab\",\n      \"pmids\": [\"38740432\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ACKR1 (DARC) is an atypical, non-G-protein-coupled seven-transmembrane chemokine receptor expressed on erythrocytes and post-capillary venular endothelial cells that binds both CXC and CC pro-inflammatory chemokines (but not lymphoid chemokines) without conventional signal transduction, functioning as a chemokine sink/reservoir on erythrocytes to regulate circulating chemokine levels, and as a transcytosis conduit and junctional chemokine presenter on venular endothelium to guide directional neutrophil and T-cell diapedesis; its N-terminal ectodomain—where sulphated tyrosines 30 and 41 are critical—also serves as the obligate receptor for Plasmodium vivax/knowlesi invasion of red blood cells, the target for S. aureus hemolytic leukocidins (LukED/HlgAB), and a binding partner for the metastasis suppressor KAI1/CD82 that triggers tumor cell senescence.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ACKR1 (DARC/Duffy) is an atypical seven-transmembrane chemokine receptor that binds pro-inflammatory CXC and CC chemokines without coupling to G-protein signaling, instead acting as a high-capacity chemokine handling system that shapes inflammation [#1, #3, #22]. On erythrocytes it functions as a chemokine sink/reservoir: it internalizes and sequesters ligands such as CXCL1, CCL2, CCL5, and CXCL8 from plasma, and its loss elevates circulating and tissue chemokine levels and exaggerates inflammatory leukocyte infiltration [#0, #1, #9]. Release of reservoir chemokines is triggered by clotting and heparan sulfate, and the common rs12075 (Asp42Gly) variant is a major determinant of erythrocyte chemokine-binding capacity [#10]. On post-capillary venular endothelium, where it concentrates at cell-cell junctions, ACKR1 mediates abluminal-to-luminal transcytosis of chemokines and presents them as junctional depots—notably neutrophil-derived CXCL2—to direct unidirectional transendothelial neutrophil and T-cell migration [#13, #16, #18, #21]. Ligand recognition depends on a sulphated N-terminal ectodomain in which tyrosine 30 supports CXCL8 binding and tyrosine 41 supports binding of other chemokines [#4]. This same ectodomain is the obligate erythrocyte receptor for Plasmodium vivax/knowlesi invasion: binding of the parasite Duffy-binding protein RII drives its dimerization, and the sulphated tyrosine 41 docks into a charged pocket on PvDBP-RII, with conformational exposure of this site on immature reticulocytes explaining parasite tropism [#4, #11, #12, #23, #17]. The N-terminal ectodomain is also the receptor for the Staphylococcus aureus leukocidins LukED and HlgAB, mediating erythrocyte lysis, endothelial injury, and toxin lethality in vivo [#14, #19]. Independently, endothelial and bone-marrow-macrophage ACKR1 binds the metastasis suppressor KAI1/CD82, stabilizing its surface expression to induce tumor-cell senescence and to enforce TGF-\\u03b21/Smad3-mediated quiescence of long-term hematopoietic stem cells [#5, #15].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that erythrocyte DARC actively internalizes chemokine ligands and that erythroid and endothelial DARC are independently regulated, defining DARC as a chemokine-handling receptor rather than a passive binder.\",\n      \"evidence\": \"Radiolabeled ligand internalization in transfectants plus IHC and biochemistry in Duffy-negative tissues\",\n      \"pmids\": [\"7699323\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether internalized chemokine is degraded or recycled\", \"No demonstration of a signaling-independent mechanism\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Knockout mice showed that DARC functions as a chemokine sink modulating inflammation intensity and neutrophil migration, moving the receptor from in vitro binder to in vivo immunoregulator.\",\n      \"evidence\": \"Two independent Darc-null mouse lines challenged with LPS/thioglycolate, with erythrocyte chemokine-binding assays\",\n      \"pmids\": [\"10961863\", \"10757794\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Could not separate erythroid from endothelial contributions\", \"Receptor appeared largely redundant for development and most immune parameters\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated chemokine selectivity (pro-inflammatory but not lymphoid) and that DARC binding silences chemokine activity without triggering Ca2+ flux, defining its non-signaling decoy/scavenger character.\",\n      \"evidence\": \"Competitive binding of 20 chemokines, Ca2+ flux assay in CCR2B cells, KO mice\",\n      \"pmids\": [\"13679391\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the fate of bound chemokine on endothelium\", \"Mechanism of presentation versus sequestration unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Mapped the structural basis of ligand recognition to sulphated tyrosines, showing Tyr41 and Tyr30 differentially govern chemokine and parasite-protein binding via the N-terminal ectodomain.\",\n      \"evidence\": \"Tyr-to-Phe mutagenesis, cell-based binding, and soluble peptide inhibition of PvDBP/PkDaBP\",\n      \"pmids\": [\"15720550\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic structure of the sulphated interface at this stage\", \"Did not address conformational regulation of the ectodomain\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Linked DARC to tumor biology in two ways: as a direct KAI1/CD82 binding partner inducing tumor-cell senescence, and as an erythrocyte clearer of angiogenic chemokines limiting tumor vascularization.\",\n      \"evidence\": \"Yeast two-hybrid plus KO metastasis model; erythrocyte chemokine clearance assays and DARC-KO prostate tumor model\",\n      \"pmids\": [\"16862154\", \"16394268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the structural KAI1-binding interface on DARC\", \"Downstream senescence pathway only partially mapped (TBX2, p21)\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Extended the senescence/anti-angiogenic role to endothelial DARC and identified a negative role in bone density via osteoclast regulation, broadening the physiological reach of chemokine handling.\",\n      \"evidence\": \"Matrigel angiogenesis assays with anti-Fy6 blockade and KO mice; QTL mapping and in vitro osteoclast assays with chemokine affinity comparisons\",\n      \"pmids\": [\"17955335\", \"17416748\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab studies\", \"Causal chemokine intermediaries in osteoclast and angiogenesis phenotypes not fully defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Bone-marrow chimeras separated erythrocyte from endothelial DARC, showing erythrocyte DARC sets plasma chemokine levels while endothelial DARC governs leukocyte adhesion and transmigration.\",\n      \"evidence\": \"Darc-/- mice with bone marrow chimeras in LPS acute lung injury, ELISA and flow cytometry\",\n      \"pmids\": [\"19499525\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of endothelial chemokine presentation not yet defined\", \"Did not address junctional localization\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected reservoir handling to genetics and to cell-adhesion modulation, with rs12075 controlling erythrocyte chemokine binding and DARC tuning integrin activation on reticulocytes.\",\n      \"evidence\": \"GWAS (n=9598) with ex vivo chemokine-release assays; static adhesion and conformation-sensitive integrin assays on sickle reticulocytes\",\n      \"pmids\": [\"20040767\", \"21088296\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Release mechanism inferred from ex vivo assays, not reconstituted\", \"Integrin modulation shown for clustering rather than affinity change in a single system\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined the structural mechanism of parasite engagement (PvDBP-RII dimerization-coupled binding with the ectodomain forming an amphipathic helix) and established endothelial DARC as the transcytosis conduit required for CNS inflammation.\",\n      \"evidence\": \"X-ray crystallography, NMR, ITC and RBC binding mutagenesis for PvDBP; BBB transcytosis model and EAE chimeras for endothelial function\",\n      \"pmids\": [\"21743458\", \"24415938\", \"24625696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of physiological invasion complexes on intact erythrocytes not directly observed\", \"Transcytosis machinery cooperating with DARC not identified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified DARC as the erythrocyte receptor for S. aureus leukocidins LukED and HlgAB, with expression level dictating lysis susceptibility and supporting bacterial hemoglobin acquisition.\",\n      \"evidence\": \"Natural human polymorphism analysis, DARC overexpression sufficiency, direct binding and hemolysis assays\",\n      \"pmids\": [\"26320997\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve distinct toxin-binding regions structurally\", \"In vivo relevance addressed only later\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed bone-marrow macrophage DARC binds and stabilizes CD82 on hematopoietic stem cells to enforce TGF-\\u03b21/Smad3 quiescence, generalizing the DARC-KAI1 senescence axis to stem-cell maintenance.\",\n      \"evidence\": \"Cd82-/- mice, macrophage ablation, flow cytometry and TGF-\\u03b21/Smad3 signaling and cell-cycle assays\",\n      \"pmids\": [\"26996598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct DARC-CD82 binding interface not structurally defined\", \"Whether chemokine binding influences this interaction unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Pinpointed the endothelial niche (post-capillary venules, junction-concentrated) where leukocyte adhesion occurs, and showed conformational exposure of the DBP-binding site on immature reticulocytes explains P. vivax tropism.\",\n      \"evidence\": \"Purpose-built anti-DARC monoclonal antibodies, tissue immunostaining and intravital microscopy; reticulocyte maturation flow cytometry with DBP binding; pancreatic cancer DARC knockdown CXCR2/STAT3 assays\",\n      \"pmids\": [\"28526034\", \"28754683\", \"28214673\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reticulocyte conformational change inferred without direct structure\", \"CXCR2/STAT3 suppression shown in single cancer model\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved how endothelial ACKR1 directs migration: it presents neutrophil-derived CXCL2 as a junctional depot enabling unidirectional luminal-to-abluminal neutrophil transmigration.\",\n      \"evidence\": \"Confocal intravital microscopy of cytokine-stimulated cremaster muscle in ACKR1-KO mice\",\n      \"pmids\": [\"30446388\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of directionality not fully defined\", \"Generalizability to other chemokines/leukocytes addressed separately\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established endothelial DARC as the critical in vivo target of S. aureus leukocidins for lethality, and refined erythroid DARC's conformation-dependent handling of CXCL12.\",\n      \"evidence\": \"Endothelial conditional DARC-KO mice with toxin and bloodstream infection models; CXCL12/SDF-1 binding assays across erythroid maturation with IL-8/antibody induction\",\n      \"pmids\": [\"30799265\", \"31700087\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CXCL12 binding consequences for trafficking not established\", \"Conformational switch mechanism inferred indirectly\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed endothelial ACKR1 biases T-cell diapedesis toward the transcellular route at the blood-brain barrier, extending its junctional migratory role beyond neutrophils.\",\n      \"evidence\": \"RNA-seq, ACKR1 KO in primary brain microvascular endothelial cells under flow, T-cell diapedesis assay\",\n      \"pmids\": [\"34524684\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single in vitro system\", \"Mechanistic link between ACKR1 and transcellular pathway selection unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided atomic detail of the sulphated interaction, showing DARC Tyr41-sulphate docks into a charged PvDBP-RII pocket, and defining a growth-inhibitory vaccine epitope.\",\n      \"evidence\": \"Crystal structure of PvDBP-RII with sulphated DARC peptide, MD simulations, affinity measurements and parasite growth inhibition\",\n      \"pmids\": [\"37336887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full receptor context on intact reticulocytes not captured\", \"Translation to broadly protective vaccine not yet achieved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded endothelial ACKR1's pathological roles—FOLR2+ macrophage recruitment in tendon repair and an ACKR1/NF-\\u03baB/SPP1 axis driving aortic dissection—and identified anti-ACKR1 autoantibodies mediating endothelial ADCC after COVID-19.\",\n      \"evidence\": \"Bone marrow chimeras with scRNA-seq/proteomics (tendon); gain/loss-of-function ECs with NF-\\u03baB analysis and TAAD mouse model; patient IgG ADCC assays with blocking peptide rescue\",\n      \"pmids\": [\"38714649\", \"39692014\", \"38740432\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each finding from a single lab/model\", \"Direct versus indirect role of ACKR1 in NF-\\u03baB/SPP1 signaling not fully separated\", \"Autoantibody clinical relevance not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ACKR1's non-signaling chemokine binding, transcytosis, junctional presentation, and protein-protein partnerships (KAI1/CD82) are coordinated at the molecular level—and which trafficking machinery executes transcytosis and EV secretion—remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of the chemokine-bound endothelial receptor at junctions\", \"Transcytosis and EV-secretion machinery unidentified\", \"Structural basis of the DARC-CD82 interaction unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [4, 11, 12, 14, 23, 17]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [3, 18]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [0, 1, 9, 10]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 27, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 16, 18]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 2, 9, 18]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [13, 18, 21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 12, 14, 19, 23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 25, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CD82\", \"CXCL2\", \"CCL2\", \"CXCL8\", \"CXCL12\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}